Skip to main content
. 2010 Nov 10;2010(11):CD005197. doi: 10.1002/14651858.CD005197.pub3

Comparison 4. Carbapenem vs. other.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 All‐cause mortality 22 4431 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [0.87, 1.55]
1.1 ceftazidime 8 2028 Risk Ratio (M‐H, Fixed, 95% CI) 0.91 [0.54, 1.54]
1.2 cefepime 8 1570 Risk Ratio (M‐H, Fixed, 95% CI) 0.84 [0.52, 1.37]
1.3 cefoperazone‐sulbactam 1 135 Risk Ratio (M‐H, Fixed, 95% CI) 1.18 [0.42, 3.34]
1.4 piperacillin‐tazobactam 4 398 Risk Ratio (M‐H, Fixed, 95% CI) 2.19 [1.05, 4.57]
1.5 aztreonam 1 300 Risk Ratio (M‐H, Fixed, 95% CI) 3.77 [1.07, 13.23]
2 All‐cause mortality ‐ sensitivity analysis allocation concealment 22 4431 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [0.87, 1.55]
2.1 adequate 10 2169 Risk Ratio (M‐H, Fixed, 95% CI) 1.05 [0.66, 1.65]
2.2 unclear 11 2213 Risk Ratio (M‐H, Fixed, 95% CI) 1.25 [0.85, 1.83]
2.3 inadequate 1 49 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.07, 15.73]
3 Infection related mortality 17 3469 Risk Ratio (M‐H, Fixed, 95% CI) 0.96 [0.60, 1.52]
3.1 ceftazidime 8 2025 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.49, 1.85]
3.2 cefepime 5 832 Risk Ratio (M‐H, Fixed, 95% CI) 1.17 [0.46, 3.00]
3.3 cefoperazone‐sulbactam 1 135 Risk Ratio (M‐H, Fixed, 95% CI) 0.28 [0.06, 1.31]
3.4 piperacillin‐tazobactam 2 177 Risk Ratio (M‐H, Fixed, 95% CI) 2.71 [0.11, 64.65]
3.5 aztreonam 1 300 Risk Ratio (M‐H, Fixed, 95% CI) 1.71 [0.42, 7.03]
4 Clinical failure 25 5159 Risk Ratio (M‐H, Fixed, 95% CI) 0.94 [0.89, 1.00]
4.1 ceftazidime 9 2340 Risk Ratio (M‐H, Fixed, 95% CI) 0.86 [0.80, 0.94]
4.2 cefepime 7 1092 Risk Ratio (M‐H, Fixed, 95% CI) 1.08 [0.91, 1.28]
4.3 cefoperazone‐sulbactam 3 776 Risk Ratio (M‐H, Fixed, 95% CI) 1.19 [0.99, 1.43]
4.4 piperacillin‐tazobactam 5 666 Risk Ratio (M‐H, Fixed, 95% CI) 0.93 [0.80, 1.07]
4.5 aztreonam 1 285 Risk Ratio (M‐H, Fixed, 95% CI) 0.86 [0.69, 1.07]
5 Clinical failure ‐ sensitivity analysis allocation concealment 24 4874 Risk Ratio (M‐H, Fixed, 95% CI) 0.95 [0.89, 1.01]
5.1 adequate 11 2447 Risk Ratio (M‐H, Fixed, 95% CI) 0.98 [0.89, 1.08]
5.2 unclear 12 2378 Risk Ratio (M‐H, Fixed, 95% CI) 0.93 [0.85, 1.01]
5.3 inadequate 1 49 Risk Ratio (M‐H, Fixed, 95% CI) 0.39 [0.12, 1.30]
6 Microbiological failure 18 1266 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.88, 1.08]
6.1 ceftazidime 8 633 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.86, 1.10]
6.2 cefepime 5 307 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.77, 1.32]
6.3 cefoperazone‐sulbactam 2 152 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.52, 2.47]
6.4 piperacillin‐tazobactam 2 69 Risk Ratio (M‐H, Fixed, 95% CI) 1.09 [0.88, 1.35]
6.5 aztreonam 1 105 Risk Ratio (M‐H, Fixed, 95% CI) 0.63 [0.34, 1.17]
7 Any modifications 10 1968 Risk Ratio (M‐H, Fixed, 95% CI) 0.89 [0.82, 0.96]
7.1 ceftazidime 7 1656 Risk Ratio (M‐H, Fixed, 95% CI) 0.86 [0.79, 0.94]
7.2 cefoperazone‐sulbactam 1 135 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.75, 1.37]
7.3 piperacillin‐tazobactam 2 177 Risk Ratio (M‐H, Fixed, 95% CI) 1.00 [0.82, 1.22]
8 Glycopeptide addition 11   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
8.1 ceftazidime 6 1429 Risk Ratio (M‐H, Fixed, 95% CI) 0.70 [0.57, 0.86]
8.2 cefepime 2 269 Risk Ratio (M‐H, Fixed, 95% CI) 1.70 [1.12, 2.59]
8.3 cefoperazone‐sulbactam 1 135 Risk Ratio (M‐H, Fixed, 95% CI) 1.10 [0.71, 1.71]
8.4 piperacillin‐tazobactam 2 219 Risk Ratio (M‐H, Fixed, 95% CI) 1.44 [1.04, 2.00]
9 Antifungal drug addition 14   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.1 ceftazidime 7 1585 Risk Ratio (M‐H, Fixed, 95% CI) 1.10 [0.84, 1.44]
9.2 cefepime 3 318 Risk Ratio (M‐H, Fixed, 95% CI) 1.73 [0.93, 3.23]
9.3 cefoperazone‐sulbactam 1 135 Risk Ratio (M‐H, Fixed, 95% CI) 1.96 [1.13, 3.39]
9.4 piperacillin‐tazobactam 3 356 Risk Ratio (M‐H, Fixed, 95% CI) 0.75 [0.56, 1.01]
10 Superinfection ‐ any 10 2905 Risk Ratio (M‐H, Fixed, 95% CI) 0.90 [0.71, 1.12]
10.1 ceftazidime 5 1578 Risk Ratio (M‐H, Fixed, 95% CI) 0.83 [0.62, 1.09]
10.2 cefepime 2 455 Risk Ratio (M‐H, Fixed, 95% CI) 1.19 [0.58, 2.48]
10.3 cefoperazone‐sulbactam 2 572 Risk Ratio (M‐H, Fixed, 95% CI) 0.97 [0.59, 1.58]
10.4 aztreonam 1 300 Risk Ratio (M‐H, Fixed, 95% CI) 1.03 [0.34, 3.11]
11 Superinfection ‐ fungal 6 1586 Risk Ratio (M‐H, Fixed, 95% CI) 0.98 [0.53, 1.81]
11.1 ceftazidime 2 466 Risk Ratio (M‐H, Fixed, 95% CI) 1.59 [0.48, 5.34]
11.2 cefepime 1 248 Risk Ratio (M‐H, Fixed, 95% CI) 1.33 [0.30, 5.83]
11.3 cefoperazone‐sulbactam 2 572 Risk Ratio (M‐H, Fixed, 95% CI) 0.73 [0.30, 1.75]
11.4 aztreonam 1 300 Risk Ratio (M‐H, Fixed, 95% CI) 0.34 [0.01, 8.34]
12 Superinfection ‐ bacterial 6 1705 Risk Ratio (M‐H, Fixed, 95% CI) 0.83 [0.49, 1.41]
12.1 ceftazidime 1 378 Risk Ratio (M‐H, Fixed, 95% CI) 1.86 [0.34, 10.02]
12.2 cefepime 2 455 Risk Ratio (M‐H, Fixed, 95% CI) 0.74 [0.31, 1.79]
12.3 cefoperazone‐sulbactam 2 572 Risk Ratio (M‐H, Fixed, 95% CI) 0.80 [0.38, 1.70]
12.4 aztreonam 1 300 Risk Ratio (M‐H, Fixed, 95% CI) 0.34 [0.01, 8.34]
13 Adverse events ‐ any 14   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
13.1 meropenem vs. other 1 341 Risk Ratio (M‐H, Fixed, 95% CI) 0.76 [0.29, 2.01]
13.2 imipenem vs. other 10 2901 Risk Ratio (M‐H, Fixed, 95% CI) 1.68 [1.44, 1.96]
13.3 Combined/other vs. other 3 313 Risk Ratio (M‐H, Fixed, 95% CI) 1.13 [0.70, 1.82]
14 Adverse events requiring discontinuation 11 2213 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.68, 1.90]
14.1 meropenem vs. other 5 1185 Risk Ratio (M‐H, Fixed, 95% CI) 1.35 [0.70, 2.61]
14.2 imipenem vs. other 5 912 Risk Ratio (M‐H, Fixed, 95% CI) 0.85 [0.36, 1.99]
14.3 Combined/other vs. other 1 116 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Adverse events ‐ seizures 11 2966 Risk Ratio (M‐H, Fixed, 95% CI) 2.80 [1.05, 7.42]
15.1 meropenem vs. other 2 582 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.07, 16.52]
15.2 imipenem vs. other 8 2268 Risk Ratio (M‐H, Fixed, 95% CI) 3.18 [1.10, 9.18]
15.3 Combined/other vs. other 1 116 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Adverse events ‐ pseudomembranous colitis 7 2408 Risk Ratio (M‐H, Fixed, 95% CI) 1.80 [1.16, 2.77]
16.1 cehalosporin +/‐ beta‐lactamase 6 2025 Risk Ratio (M‐H, Fixed, 95% CI) 1.94 [1.24, 3.04]
16.2 aztreonam 1 383 Risk Ratio (M‐H, Fixed, 95% CI) 0.19 [0.01, 4.03]
17 Adverse events ‐ gastrointestinal other than PMC 14 3484 Risk Ratio (M‐H, Fixed, 95% CI) 2.00 [1.63, 2.46]
17.1 piperacillin‐tazobactam 2 179 Risk Ratio (M‐H, Fixed, 95% CI) 1.32 [0.84, 2.09]
17.2 cehalosporin +/‐ beta‐lactamase 11 2922 Risk Ratio (M‐H, Fixed, 95% CI) 2.46 [1.93, 3.14]
17.3 aztreonam 1 383 Risk Ratio (M‐H, Fixed, 95% CI) 0.61 [0.28, 1.31]